Rhythm Pharmaceuticals, Inc. announced that Keith Gottesdiener, M.D., intends to step down as Chief Executive Officer, President and a member of the Board of Directors. The Board has formed a search committee and retained an executive search firm to assist in identifying Dr. Gottesdiener's successor. Dr. Gottesdiener plans to serve in his current role until the completion of the Company's submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.75 USD | +0.52% |
|
+3.29% | -7.00% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.00% | 2.61B | |
+16.45% | 122B | |
+21.96% | 116B | |
+23.73% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.52% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- RYTM Stock
- News Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Resignation of Keith Gottesdiener as Chief Executive Officer, President and A Member of the Board of Directors